Health insurance: what are more members worth when care costs rise? $CNC, $CVS, $OSCR, $UNH

01What an additional member actually adds

A health insurer sells a promise before it knows the final cost of keeping that promise. A new member brings premium income, but also an obligation to finance covered care. Whether that member creates value depends on the relationship between the premium, the expected medical expense, the cost of serving the contract and the capital needed to absorb surprises. Membership growth is therefore the beginning of the analysis. The useful question is how much durable, distributable profit remains after the obligations attached to that growth have been met.

Imagine two plans adding the same number of people. One has priced for rising outpatient utilization, negotiated a workable provider network and budgeted adequately for administration. The other wins enrollment with a premium that leaves little room for a change in patient needs. Their growth rates can look identical while their economics move in opposite directions. Size helps distribute fixed costs, but size also multiplies an underwriting error. The mechanism is easy to understand once you treat each additional policy as both revenue and a future stream of uncertain expenses.

Centene, CVS Health, Oscar Health and UnitedHealth Group have overlapping insurance exposures, yet their business models differ substantially. Centene combines large government program businesses with Marketplace coverage. CVS includes Aetna, pharmacy services and retail pharmacies. Oscar is concentrated in individual insurance. UnitedHealth combines UnitedHealthcare with the care, pharmacy and information businesses of Optum. You cannot interpret the same growth headline identically across these structures.

The information cut-off is September 25, 2026. The financial comparison uses the quarter ended June 30, with later developments dated separately. Reported results, management guidance and illustrative calculations have different evidentiary weight throughout the discussion. The objective is to give you a reusable method for reading insurance earnings: identify the population, establish the revenue denominator, reconstruct the medical cost trend, examine the liabilities and only then consider the claim belonging to each common share.

02Count member months, covered risks and service relationships

A membership number is a snapshot. Premium income is earned over time. If a person joins on June 29, that enrollment contributes to quarter-end membership but hardly to the quarter's earned premium. A person who leaves in April has the opposite effect. For operating analysis, member months often provide a better bridge between population and revenue. Average membership, quarter-end membership and annual enrollment are related measurements, but they answer different questions. Mixing them can create an apparent change in revenue per member that is merely a timing effect.

The type of coverage matters just as much. A prescription drug plan does not insure the same collection of medical services as a comprehensive medical plan. A high-acuity Medicaid population does not have the same expected claims as a lower-acuity commercial population. A Medicare Supplement relationship differs from a Medicare Advantage contract. Counting every person as an interchangeable unit conceals the benefits promised, the expected spending and the amount of revenue associated with each relationship.

Administrative services add another distinction. Under an administrative services contract, an employer may bear the medical claims risk while the insurer receives a fee for processing claims, maintaining a network or providing related services. Such a member can support profitable revenue without producing the same premium and medical expense as a fully insured member. At an integrated group, pharmacy customers, insurance members and patients may also overlap. Adding the populations together does not produce a reliable count of unique customers.

A useful membership bridge asks four questions. How many people entered or left? Which products changed? How many months of coverage were earned? Who bears the claims risk? Before you calculate revenue per person, establish whether the numerator includes fees, investment income, product sales or insurance premiums. The same discipline applies to retention: a smaller, better-priced insured population can improve economics, while rapid growth in a low-margin contract can require more capital without improving returns to shareholders.

03The small arithmetic that makes medical trend powerful

Consider a purely illustrative monthly policy collecting $600 of premium, incurring $540 of medical expense and consuming $42 of administration. The remaining $18 is an underwriting contribution before financing costs, taxes and other items. The medical expense ratio is 90%, yet the underwriting contribution is only 3% of premium. This is why a seemingly small change in claims can have a large effect on earnings. A two-percentage-point increase in the medical expense ratio consumes $12 of the original $18 contribution if everything else stays constant.

Now suppose medical expense rises 8% while premium rises 5%. Medical expense becomes $583.20 and premium becomes $630. If administration remains $42, contribution falls to $4.80 despite higher revenue. If administration also rises, the outcome weakens further. The problem is the gap between the growth rates applied to unequal bases. An 8% medical trend does not mean that premiums must rise exactly 8% to preserve dollar earnings, nor does it tell you the rate required to preserve a percentage margin. Those are separate calculations.

Medical trend itself combines several forces. Patients may use more services, providers may charge higher contracted prices, treatment intensity may increase, or the population may need more complex care. A plan can experience a better mix of patients alongside higher underlying unit costs. It can also have fewer hospital admissions but higher spending per admission. A single trend estimate compresses these effects and should be unpacked when management explains an earnings change.

For a quick sensitivity test, multiply the relevant premium base by a one-percentage-point change in the medical expense ratio. A hypothetical $10 billion premium base has $100 million of pretax exposure to that change, before offsets and interactions. This is a sensitivity, not a forecast. It assumes the premium denominator stays fixed and ignores possible contractual protections. The calculation is useful because it puts a vague comment about cost pressure into scale without pretending you can predict the next quarter's claims precisely.

04Read the denominator before reading the ratio

Companies use labels including medical loss ratio, medical benefit ratio, medical care ratio and health benefits ratio. All connect medical expense with an insurance revenue base, but you should read each definition before comparing the numbers. Reinsurance treatment, risk adjustment, program mix and the scope of the reporting entity can differ. An insurer with a larger high-acuity government population can report a higher ratio while operating an economically viable business. A lower ratio at another company does not establish superior care management by itself.

The regulatory medical loss ratio is a further, distinct calculation. CMS describes minimum spending requirements of 80% for individual and small-group markets and 85% for large-group markets, with qualifying quality-improvement spending included and prescribed adjustments. These requirements operate through regulatory reporting rules. They are not a simple instruction to compare one consolidated quarterly earnings ratio with 80% and declare that a rebate is owed. Geography, market, measurement period and the statutory methodology matter. CMS explanation and reporting framework.

The complementary percentage is also easy to misuse. If a company reports a 90% claims ratio, the remaining 10% must still support administration, distribution, technology, compliance and any underwriting profit. It is not a 10% net margin. Investment income can contribute to earnings, while interest expense, taxes and noninsurance operations create additional differences. A group income statement is broader than its insurance claims ratio, especially for CVS and UnitedHealth.

Your most informative comparison is often within the same company, using the same definition and a similar population over time. Then examine what changed: pricing, product exits, reserve estimates, mix or service use. For peers, construct a comparison of mechanisms before a ranking of percentages. Keeping each company's measure and scope visible preserves useful information when businesses insure different risks and recognize different kinds of revenue.

05ACA insurance: pricing the pool and estimating the transfer

Individual Marketplace insurance creates two connected estimation problems. The insurer must estimate the cost of its own members, and it must estimate its position within the broader risk pool used for risk adjustment. The permanent risk-adjustment system transfers funds from covered plans with relatively lower-risk populations toward plans with relatively higher-risk populations under the applicable methodology. It aims to reduce the incentive to compete mainly by attracting healthier people. CMS publishes program explanations and annual transfer reports. CMS risk-adjustment resources.

The word “relative” is crucial. Your own claims experience can develop broadly as expected while information about the rest of the market changes the expected transfer. The issuer therefore has uncertainty in both the medical expense numerator and the net premium denominator. A revision to a risk-adjustment payable may improve reported revenue without meaning that patients suddenly used fewer services. Conversely, a larger expected transfer can reduce net premium even when gross enrollment and gross premium are growing.

Use an illustrative example. A plan earns $1 billion of gross premium and estimates a $100 million net transfer payable. Its simplified premium after the transfer is $900 million. If the estimate later falls to $80 million, the $20 million improvement concerns the estimate of the transfer. It is economically meaningful, but it should not automatically be extrapolated into the next policy year's margin. The plan must still price the next cohort using current market morbidity and the rules applicable to that period.

Eligibility, premium collection and the durability of enrollment also matter. A selected plan, an effectuated policy and a paid month of coverage are different stages. Retroactive enrollment corrections can affect both membership and recognized premium. Changes in subsidies or verification requirements can alter who remains insured and the composition of the pool. For investment analysis, follow the disclosed exposure and final applicable policy documents; do not turn a political headline into a fixed revenue forecast before the implementation details and the company's response are clear.

06Medicare Advantage: payment, benefits and care intensity

Medicare Advantage economics involve payments linked to a regulated framework, risk adjustment, plan bids, benefit design and quality measures. You should distinguish Medicare Advantage from stand-alone prescription drug coverage and from Medicare Supplement insurance. These products share a Medicare connection but do not carry identical benefits, funding mechanisms or risks. A consolidated Medicare segment can therefore change even when no single underlying product experiences the same degree of improvement.

The annual payment announcement is an input to planning, not a company-specific margin guarantee. CMS published its 2027 Medicare Advantage and Part D rate announcement on April 6, 2026. The final framework and a carrier's eventual product decisions are more useful than an earlier proposal when evaluating the next year. Even an increase in expected payments must be compared with medical trend, changes in population risk, quality effects and the cost of the benefits offered. CMS 2027 rate announcement.

Think of the business as a sequence. The carrier estimates future cost, designs benefits and a network, submits its offering and then enrolls members. Actual utilization subsequently reveals how accurate those assumptions were. The ability to change an already established offering is constrained by the contract and regulatory calendar. A cost shock can therefore affect profitability before a new pricing and benefit cycle takes effect. Better management of care may help sooner, but it must produce evidence in utilization, expense and service quality.

Risk coding deserves particular care in your interpretation. Payments adjusted for health status can reflect the genuine needs of a population, while documentation and audit rules determine what is supportable. More recorded diagnoses cannot be assumed to create permanent economic value independent of care delivery and compliance. When you evaluate a recovery, ask whether it rests on sustainable benefits, appropriate care, valid documentation and adequate payment for actual risk. A plan that regains margin by changing its mix may be economically healthier even if it serves fewer members.

07Medicaid: when the population changes faster than the rate

Medicaid managed care operates through state contracts and population-specific arrangements. The relevant question is not simply whether a state pays more next year. You need to understand which covered groups are growing, which benefits are included, how recent cost experience enters rates and when a contractual adjustment reaches the income statement. CMS's current rate-development resources describe the actuarial-soundness framework for state capitation rates, including the 2026–2027 guide. That framework does not remove timing differences between emerging claims and the payment period. Medicaid rate-review resources.

Membership can decline while average medical expense rises. If people with lower expected utilization leave coverage at a faster rate, the remaining population may be more expensive even without an unusual increase in the cost of each service. A decline in the member count then offers little reassurance about the claims ratio. The insurer has fewer premiums to spread across fixed infrastructure and a potentially more demanding population to serve.

Consider a hypothetical contract priced using an expected monthly claim cost of $450. If the enrolled population changes and expected claims become $480, a later rate increase may repair the economics prospectively. It does not necessarily recover every dollar lost while the old rate remained in place. Whether there is retroactive compensation, a risk corridor or another protection depends on the actual contract. You should not assume that every state arrangement automatically makes an insurer whole after a cost surprise.

For a diversified carrier, favorable commercial results can obscure Medicaid pressure. Segment disclosure helps reveal that tension. Watch rate implementation, utilization, acuity, membership transitions and contract renewals together. An announced contract win is also only one step: readiness spending, implementation work, provider access and eventual member assignment determine the economic result. A winning bid can create a useful long-term relationship, but it can require cash and management attention before it generates a satisfactory return.

08Claims reserves: what changed, and which period did it change?

Medical care is often delivered before the final bill is received or paid. Insurers therefore estimate liabilities for claims already incurred, including claims not yet reported or fully processed. As information arrives, those estimates change. Favorable development means the earlier estimate exceeded the now-expected cost; unfavorable development means the earlier estimate was insufficient. Both are part of normal insurance accounting, and neither alone proves that management was unusually conservative or aggressive.

The service period matters. A favorable adjustment related to the first quarter can appear in second-quarter earnings. That is prior-period development, but it is still associated with the current calendar year. A revision to the previous policy year's risk-adjustment transfer is another kind of estimate. A premium deficiency reserve, meanwhile, concerns expected losses under the relevant accounting framework. These concepts can all affect the comparison of reported results, yet they should not be merged into one vaguely defined “reserve benefit.”

A useful earnings bridge separates current-period medical experience, prior-period claims development, risk-adjustment revisions and unusual comparison items. Ask whether the improvement reduces a liability, increases net revenue or avoids an expense recorded in the comparison period. The cash timing can differ from the earnings timing in each case. A favorable estimate may strengthen equity today while the associated settlement occurs later. It is still an estimate until the underlying obligations are sufficiently resolved.

Days claims payable can provide context, but it is not a standalone verdict on reserve adequacy. Payment timing, seasonality, provider settlements and program mix can move the figure. A shorter payment cycle can release a balance-sheet liability while using cash. A longer cycle can increase operating cash flow while leaving obligations unpaid. Compare the reserve roll-forward with the claims ratio and cash-flow statement, and look for a coherent explanation. The goal is to understand the economic period benefiting from the change, not to label every reserve adjustment as suspicious.

09Cash, insurance capital and reinsurance have different jobs

A large cash balance can coexist with limited cash available to common shareholders. Insurance subsidiaries hold assets to settle claims, meet regulatory requirements and support ongoing operations. The parent holding company has separate needs, including debt service and corporate expenses. Transfers from regulated subsidiaries can be subject to restrictions. When a release reports consolidated cash, your next question is where that cash sits and what obligations it supports. Subtracting all consolidated cash from parent debt can overstate financial flexibility.

Operating cash flow also has a distinctive pattern in insurance. Premium receipts may precede medical payments, and annual risk-adjustment settlements can be substantial. Growing enrollment can temporarily expand cash because liabilities accumulate alongside receipts. The increase is not automatically free cash flow available for a dividend or acquisition. To interpret it, reconcile cash with claims payable, government payables, receivables and the calendar of expected settlements. Strong cash generation is most persuasive when it survives those timing explanations.

Reinsurance can reduce exposure and capital requirements by transferring part of the risk to another party. The economics depend on the premium ceded, commissions, coverage conditions, counterparty and accounting treatment. A quota-share agreement transfers a share of a book's economics; excess-of-loss protection responds differently. Neither arrangement makes the underlying medical trend irrelevant. The insurer may exchange some future earnings for protection or capital efficiency, which can be sensible without being costless.

A useful capital assessment has three layers. First identify operating assets required for policyholders. Then establish parent resources and obligations. Finally examine the incremental capital needed to support the next unit of growth. A business can improve reported earnings while still needing to retain most of them because its enrollment base is expanding. Conversely, slower growth can release capital even when it reduces the headline revenue trajectory. Value depends on the return on the capital retained, not merely on the amount of cash shown on the consolidated balance sheet.

10Centene: the segment differences inside $CNC

Centene's July 28 release reported second-quarter revenue of $53.579 billion, premium and service revenue of $44.375 billion and an overall health benefits ratio of 89.6%. GAAP diluted EPS was $2.19 and adjusted diluted EPS was $2.51. Those figures immediately illustrate the denominator problem: total revenue and premium-and-service revenue are distinct lines. You should not divide medical expense by the larger consolidated revenue number and describe the result as the company's disclosed HBR. Centene Q2 release.

The more revealing detail is the difference across businesses. Centene reported Medicaid HBR of 93.9%, Medicare HBR of 89.5% and commercial HBR of 79.2%. These figures describe different populations and product structures within one carrier. They show why the group average conceals relevant variation. They do not tell you that a Medicaid member is intrinsically less valuable than a commercial member: administration, rate adequacy, capital intensity and contract terms must also be considered.

At June 30, the company reported approximately 12.111 million Medicaid members, 3.495 million Marketplace members, 980,000 Medicare members and 8.803 million stand-alone prescription drug plan members. The PDP count belongs to a different benefit scope from comprehensive medical coverage. Centene also disclosed reclassification effects associated with the transition of certain dual-eligible members into integrated Medicare arrangements. A year-over-year member bridge therefore needs both actual enrollment changes and the classification footnotes. SEC copy of the release and tables.

The company raised its 2026 adjusted EPS floor to greater than $4.80, alongside a GAAP floor above $3.11. It identified approximately $0.50 of nonrecurring items in the Medicare and commercial businesses within the improvement to the outlook. That caveat changes how you use the new floor: the full increase is not evidence of an equally large recurring improvement in every segment. For your own model, keep the reported forecast intact and build a separate normalization bridge. Silently subtracting selected items and presenting the remainder as management's guidance would misstate what management actually said.

11Centene: capital allocation and the evidence that could change your view

Centene's quarter-end disclosures included about $20.3 billion of medical claims liabilities and $16.1 billion of total debt. The company repurchased $260 million of senior notes during the quarter. A debt repurchase is a capital-allocation event, distinct from a common-share repurchase. It can reduce future financing obligations, but its attractiveness depends on the price paid, the remaining liquidity and the competing uses of capital. The release also provides claims-payment timing and information about cash available for general corporate use, which are useful alongside the consolidated balance sheet. Centene financial tables.

Centene reaffirmed the same GAAP and adjusted EPS floors in its September 16 Form 8-K, providing a later confirmation than the July earnings release. A reaffirmation preserves the outlook; it does not turn the nonrecurring component into recurring earnings. Centene September 16 update.

Sarah London is identified as chief executive officer in the current release. For assessing management, the most useful evidence is execution against the problems the numbers reveal. Medicaid rate adequacy, accurate Marketplace assumptions, cost discipline and the handling of contract transitions offer more observable tests than broad statements about growth. Track the consistency of those explanations over successive quarters and whether the reserve roll-forward supports them.

A constructive scenario would combine adequate state rates, stable utilization and disciplined commercial pricing, allowing more of the premium dollar to reach sustainable earnings after administration. A less favorable scenario would have Medicaid acuity or service intensity outpace rate recognition while commercial improvement depends heavily on adjustments related to earlier periods. These are conditional paths, not forecasts. Their value lies in identifying which disclosures would distinguish one path from the other.

The recovery thesis would weaken if segment costs repeatedly exceeded the assumptions embedded in rates, if cash conversion relied persistently on accumulating unpaid obligations, or if a growing share of earnings improvement came from items unlikely to repeat. It would strengthen with a clearer connection between current-year underwriting, stable reserves and capital generation. A larger membership base is optional in that test. A more dependable return from the existing base can be economically more important than restoring every member who left.

12CVS: separate Aetna's recovery from the prior-year bridge

CVS reported second-quarter consolidated revenue of $106.1 billion, GAAP EPS of $2.31 and adjusted EPS of $2.58 on August 5. Its full-year adjusted EPS range increased to $7.90–$8.10. Those are group figures. The insurance question belongs primarily in Health Care Benefits, where reported MBR was 87.4% compared with 89.9% a year earlier. The release attributes improvement to government-business performance and identifies the absence of a $471 million Group Medicare Advantage premium deficiency reserve recorded in the prior-year quarter. CVS release.

The same release retained a cautious view of the remainder of 2026 because medical cost trends remained elevated. Better reported margins therefore do not establish that care inflation has disappeared.

The accompanying presentation adds an essential bridge. CVS says the second quarter benefited from approximately $500 million of changes in prior-year estimates, including individual Exchange risk adjustment and favorable development. It separately describes areas of core outperformance, primarily in Medicare, associated with medical cost management and pricing. The $500 million is therefore not a clean measure of lower current-quarter medical utilization. It is also not interchangeable with the $471 million reserve recorded in the comparison period. The two disclosures explain different parts of the earnings comparison. CVS Q2 presentation, Health Care Benefits.

For a useful interpretation, keep three boxes on your worksheet: current business performance, changes to earlier estimates and prior-year comparison effects. The reported MBR belongs above the boxes as the published result; the boxes help explain it. You do not need to dismiss the improvement to recognize that some of it has a different repeatability profile. Nor should you assume every favorable estimate can be added to future quarters indefinitely.

The segment's quarter-end medical membership was approximately 26 million, including administrative services relationships. CVS also reported that its 2026 exit from individual Exchange coverage reduced the revenue comparison. Prior-year Exchange settlements can still affect earnings after an exit because the accounting obligations do not disappear when new coverage stops. That is a useful reminder that current enrollment and current reported earnings need not refer to precisely the same economic cohort. CVS SEC release and membership definitions.

13CVS: pharmacy and care delivery change the interpretation

CVS is an integrated healthcare group. Health Services includes pharmacy benefit management and care-delivery activities, while Pharmacy & Consumer Wellness includes the retail pharmacy business. Revenue from filling prescriptions or providing pharmacy services is not equivalent to an insurance premium that finances a full range of medical claims. The consolidated revenue line therefore cannot tell you Aetna's premium growth or its underwriting margin. The same patient or prescription can also appear in more than one part of the operating system before consolidation eliminates internal transactions.

The Q2 presentation described timing effects within Health Services, including value pulled forward from the second half and pressure in its 340B business. That disclosure gives you another reason to distinguish the quarter's result from a simple annual run rate. Multiplying a strong quarter by four assumes seasonality, timing and business mix remain unchanged. Such an assumption can fail even when the quarter itself is accurately reported. CVS segment presentation.

CVS reported $11.329 billion of consolidated cash at June 30 and $61.410 billion of debt when the current and long-term debt lines are added; operating lease obligations are separate. First-half operating cash flow was $10.594 billion. These figures make the allocation question concrete: insurance resources, pharmacy working capital, debt service and dividends compete within the same group. The cash balance is not automatically available at the parent, and the debt sum is not a calculation of unrestricted net debt. CVS balance sheet and cash flows.

David Joyner is identified as chairman and CEO in the current corporate release. In an integrated business, governance and execution questions include how management measures returns across divisions, allocates shared costs and evaluates the trade-off between debt reduction and reinvestment. A transaction that improves one segment's reported economics may have a different effect after intercompany eliminations. Look for benefits at the consolidated profit and cash level, with an explanation that connects them to an actual improvement in service or operating efficiency.

A constructive CVS scenario pairs a more durable Aetna margin with stable pharmacy economics and manageable capital needs. The disconfirming evidence would be renewed insurance cost pressure after the benefit of earlier estimate revisions fades, or persistent weakness elsewhere that absorbs the improvement in insurance. The next useful catalyst is therefore a new earnings bridge showing how much of the recovery survives in current-period results. A higher group EPS forecast is informative, but the durability question requires more than a comparison of two headline EPS numbers.

14Oscar: use the September guidance, then test the seasonal bridge

Oscar's August 6 report showed second-quarter revenue of $4.880 billion, an MLR of 79.2% and operating earnings of $388.6 million. Effectuated membership at June 30 was 2,963,002. The company attributed the MLR improvement partly to pricing and partly to $164 million of favorable prior-period reserve development. Those facts support a strong reported quarter, while also telling you to separate current underwriting from reserve effects. The 2025 comparison included a risk-adjustment true-up, adding another reason not to extrapolate the year-over-year change mechanically. Oscar Q2 results.

The more recent outlook is in the September 16 Form 8-K. Oscar lowered its full-year MLR guidance to 81.0%–82.0% from 81.5%–82.5%, and raised operating-earnings guidance to $600 million–$800 million from $500 million–$700 million. Revenue guidance remained $18.7 billion–$19.0 billion and the SG&A expense-ratio range remained 15.6%–16.1%. These are management expectations, not completed annual results. The September document supersedes the earlier ranges for the metrics it updates. Oscar September 16 filing.

An arithmetic bridge makes the seasonality concrete. First-half operating earnings were $1.0927 billion. Subtracting that result from the September full-year range implies second-half operating losses of approximately $292.7 million–$492.7 million if the annual range is achieved. This is a calculation from disclosed figures, not a separate company forecast for each remaining quarter. It shows why the first half cannot be annualized casually and why a later quarterly loss would not, by itself, contradict the full-year outlook.

Your next questions should concern the assumptions behind that bridge: second-half medical expense, the premium base after risk adjustment, enrollment corrections and administrative spending. A lower full-year MLR range can coexist with an expectation of weaker second-half earnings. The correct comparison is with the seasonal path embedded in guidance, not with an imaginary year made of four identical spring quarters.

15Oscar: a share distribution is different from new share issuance

On September 18, Oscar announced that certain Thrive-affiliated funds had distributed approximately 6.3 million existing Class A shares to limited partners. The company described an in-kind distribution and said it did not represent a sale by Thrive Capital or Joshua Kushner. It also reported that affiliated holders retained approximately 67% of combined voting power after the distribution. This event changes ownership arrangements; it is not evidence that Oscar issued 6.3 million new shares to raise capital. Oscar's distribution announcement.

The recipients' eventual trading decisions are a separate question. Existing shares may change hands without changing the company's total share count, although changes in the tradable supply can influence market behavior. Economic dilution from new issuance, voting control and potential selling pressure should therefore occupy different lines in your analysis. A price reaction cannot tell you which mechanism occurred. The transaction documents and share-count disclosures do.

Oscar's June balance sheet also illustrates why cash needs context: consolidated cash was about $4.076 billion, with substantial investments, but payables to CMS were about $6.095 billion and benefits payable about $1.898 billion. Its filing distinguishes parent liquidity from insurance-subsidiary resources and describes reinsurance arrangements. These balances cannot be collapsed into an unrestricted cash-per-share figure. The same filing disclosed an expectation that roughly 250,000–300,000 members as of July 1 would be retroactively disenrolled in connection with program-integrity requirements or related laws and regulations. That was a dated expectation, not a subsequently verified final count. Oscar June Form 10-Q.

Mark Bertolini leads Oscar as CEO. On April 21, the company announced Siddhartha Sankaran’s appointment as independent board chair, effective June 4, 2026. Oscar board announcement. Board structure is relevant alongside the concentrated voting rights, but neither feature guarantees the quality of future underwriting decisions. The operating test remains whether growth produces reliable margins and appropriate capital generation. You can follow the company's evolving disclosures in the Oscar Health Stock Hub, keeping market movements separate from changes in the insurance contract economics.

16UnitedHealth: one group, several economic engines

UnitedHealth's July 16 release reported second-quarter consolidated revenue of $112.032 billion, operating earnings of approximately $8.0 billion and adjusted EPS of $6.38. UnitedHealthcare served about 48.5 million consumers, while Optum operated across a broader collection of care, pharmacy and information relationships. The group's scale is substantial, but you should not add those populations to estimate unique insurance members. The revenue composition likewise includes premiums, products, services and investment or other income. UnitedHealth Q2 results.

The financial tables show $86.956 billion of premium revenue, $13.835 billion from products, $10.018 billion from services and $1.223 billion of investment and other income for the quarter. Those components reconcile to consolidated revenue and form the accompanying composition chart. They are accounting revenue categories, not the same thing as the UnitedHealthcare and Optum segment totals. Segment transactions with one another are eliminated in consolidation, so simply adding the two segment revenue numbers would overstate the group's external revenue. UnitedHealth SEC results tables.

The group reported a medical care ratio of 86.7%. Its release also disclosed $860 million of net favorable prior-period development, with the majority associated with 2026 service dates. That wording matters: prior period does not mean prior year. A revision of first-quarter estimates recorded in the second quarter is different from a settlement relating to an older annual cohort. Both can affect quarterly comparability, and the service-date distinction helps you judge what the result says about the current year.

For valuation and operating analysis, separate the insurance and services questions. UnitedHealthcare requires adequate premium relative to benefits. Optum Health has care-delivery and risk-bearing economics of its own. Optum Rx and Optum Insight involve other service, pharmacy and technology relationships. Better performance in one business can support the group without proving that every insurance product has recovered. Conversely, a difficult insurance quarter does not identify the profitability of every Optum business.

17UnitedHealth: follow the recovery assumptions through the accounts

UnitedHealth raised its full-year adjusted EPS range to $19.50–$20.00 in July, with GAAP EPS expected at $18.45–$18.95. Its updated full-year medical care ratio expectation was 88.1%, plus or minus 25 basis points. A full-year ratio above the second-quarter result is another reminder that quarterly strength and the annual operating path are different things. Do not replace the annual forecast with the best quarterly percentage when building a valuation model. UnitedHealth guidance tables.

The June Form 10-Q discusses elevated medical trend, service and coding intensity, and the effects of fewer people served alongside favorable development. It also details balance-sheet obligations and risks. These explanations provide a more useful basis for assessing the recovery than a single EPS beat. If lower enrollment improves the quality of the book, a muted revenue comparison can coexist with stronger earnings. If the improvement instead relies heavily on estimates that later reverse, the same headline growth rate has a less durable foundation. UnitedHealth June Form 10-Q.

UnitedHealth reported $31.468 billion of cash and short-term investments at June 30, compared with $38.930 billion of medical costs payable. Short-term borrowings and current debt maturities were $3.827 billion, with another $69.501 billion of long-term debt. These categories illustrate separate obligations rather than a simple claim that one balance covers another. Evaluate their location and settlement timing before deciding how much financial flexibility belongs to the parent. UnitedHealth balance sheet.

Stephen Hemsley is identified as CEO in the current results release. Management's challenge includes coordinating a large insurance operation with multiple service businesses while maintaining the systems, provider relationships and controls required by those activities. Legal proceedings, regulatory oversight and data-security risks need to be evaluated through current filings and actual procedural developments. The existence of a proceeding should not be rewritten as a finding, and a company's own description of its position is not a court's conclusion.

A constructive scenario would show pricing and product changes matching medical needs, steadier current-year claims estimates and improving returns in care delivery. Evidence against that scenario would include repeated adverse reserve revisions, service-cost pressure exceeding the assumptions in guidance or a gap between reported earnings and cash available after operating obligations. Follow the components before deciding whether a change in the group multiple reflects a better business or simply a more optimistic extrapolation of one quarter.

18Compare the four companies without creating a false league table

The comparison table keeps each reported ratio attached to its business scope. Centene's HBR, CVS's Health Care Benefits MBR, Oscar's MLR and UnitedHealth's MCR are informative because they show how each company describes the use of its insurance revenue. They are not a standardized ranking of corporate quality. Differences in population, products, risk adjustment and reinsurance can be as important as differences in operational execution.

Start with exposure. Centene gives you a clear example of state Medicaid rates and Marketplace assumptions interacting within the same group. CVS demonstrates how an insurance recovery sits alongside pharmacy and care-delivery operations. Oscar makes the relationship between individual enrollment, risk adjustment and seasonal earnings especially visible. UnitedHealth shows why a diversified healthcare group's consolidated revenue and segment revenue require reconciliation. Each company helps answer a different part of the same economic question.

Then compare the bridges. How much improvement reflects prices and current claims? How much reflects revisions to earlier estimates? Is there an unusual prior-year charge making the comparison easier? Does the guidance change exceed what the recurring explanation can support? These questions are more portable than declaring that a ratio below a particular percentage is automatically attractive. A ratio can improve because an insurer exited an unfavorable book, which may reduce both revenue and the capital needed to operate.

Finally compare what could falsify the interpretation. For Centene, watch whether Medicaid rates and acuity converge. For CVS, watch the durability of Aetna's recovery after earlier-period benefits. For Oscar, watch the seasonal earnings bridge and the enrollment base after corrections. For UnitedHealth, watch the relationship between insurance pricing, care-delivery results and claims development. A comparison becomes useful when it tells you which future evidence would force a revision, not merely which company reported the most attractive-looking number in the last quarter.

19Catalysts are changes in evidence, not guaranteed price events

UnitedHealth has scheduled third-quarter results for October 13, 2026, before the market opens, with a call at 8:00 a.m. ET. That is an announced reporting date, not a prediction of the result. UnitedHealth September 15 announcement.

The next quarterly reports can clarify the current-year claims trend, update estimates and show whether operating cash flow converts into usable capital. Annual pricing and benefit decisions can reveal how management responds to cost pressure. State contract and rate developments matter for Medicaid; enrollment and risk-adjustment updates matter for Marketplace carriers; Medicare product and quality information matter on their own calendars. A useful catalyst list identifies the variable being tested and the evidence expected, rather than assigning a guaranteed share-price direction to a date.

Build three scenarios using the same structure. In a constructive case, premium adequacy improves, medical trend stabilizes and administrative efficiency holds without repeated help from earlier estimates. In a middle case, pricing largely catches up with care costs but margins normalize as unusual benefits fade. In an adverse case, acuity or service intensity rises faster than expected, or enrollment changes leave the remaining book harder to serve. Capital requirements and debt obligations then determine how much room management has to respond.

Assigning probabilities is optional; specifying the mechanics is not. For each case, state the premium base, medical expense assumption, administrative cost and capital retention. Do not change every input in the favorable direction without explaining why they would move together. Higher prices can improve revenue per member while reducing enrollment. A narrower network may reduce negotiated costs but change the attractiveness of the plan. Administrative savings can support margins, but inadequate service can create retention and execution problems.

The strongest disconfirmers are observations that contradict a mechanism, not a temporary stock decline. If a thesis depends on better current underwriting, recurring adverse development challenges it. If it depends on capital release, growing subsidiary requirements challenge it. If it depends on member growth, large corrections or poor retention challenge it. Writing those conditions before the next report makes it easier to update your view when evidence changes, because you have already defined what the favorable interpretation would need to demonstrate.

20Valuation: price the normalized residual, not the largest revenue line

A price-to-earnings multiple is only as useful as the earnings denominator. Reported GAAP earnings, company-adjusted earnings and your own normalized estimate are three distinct quantities. Preserve the reconciliations between them. If you remove a favorable reserve item, consider whether you are also treating unfavorable items consistently. If you value a recovery on next year's earnings, state which current costs or temporary benefits are expected to change and why.

A simple illustrative sensitivity shows the interaction between margins and multiples. Suppose an insurer has $50 billion of relevant premium, a 3% pretax underwriting margin and 500 million shares. A one-percentage-point margin improvement adds $500 million of pretax earnings, or $1 per share before tax. With an assumed 25% tax rate, that becomes $0.75 per share. This is arithmetic under fixed assumptions, not a target for any of the four companies. It excludes investment income, financing changes, service businesses and possible capital effects.

For a diversified group, a sum-of-parts framework can help you avoid applying one insurance multiple to pharmacy, care delivery and information services indiscriminately. It also introduces new uncertainty: segment allocations, internal transactions, corporate costs and debt must be handled consistently. Adding optimistic standalone values without recognizing the costs of the group structure can overstate equity value. Cross-check any result against consolidated earnings and the cash that could ultimately reach owners.

Price-to-book can provide another perspective, but book equity is not automatically excess capital. Goodwill, intangible assets, regulatory capital needs and the profitability of the book all affect its interpretation. Return on equity generated by an unusually favorable period may not persist. A low multiple can reflect uncertainty about future earnings or capital access; a higher multiple can reflect expected durability. Your task is to identify what expectations are embedded in the price you observe, using a timestamped quote if you perform the calculation, and then test those expectations against the operating evidence.

21Questions that make the next earnings report easier to read

Does more membership always improve bargaining power? It can improve scale, but local network relationships and the covered population matter. National enrollment is not a perfect measure of bargaining power in a particular city or specialty. More members also add claims, service work and capital needs. The economic gain depends on whether the incremental premium covers those obligations at a satisfactory return.

Is a lower claims ratio always good? A lower ratio can support earnings when pricing and care delivery are appropriate. Its interpretation changes if it comes from temporary estimate revisions, product exits or a different risk mix. It should also be considered alongside access, quality, administration and the regulatory calculation relevant to the product. A quarterly accounting ratio alone does not answer every question about the plan.

Can medical expense increase while the ratio improves? Yes. If the relevant premium denominator grows faster than medical expense, the ratio declines even though total claims rise. Conversely, a ratio can deteriorate during a decline in absolute claims if premium falls faster. Follow both dollars and percentages, then distinguish changes caused by enrollment from changes in the cost of serving each covered month.

Why can an insurer show strong cash flow and still retain earnings? Premium and settlement timing can temporarily increase cash, while insurance subsidiaries need assets supporting claims and required capital. Parent debt service and investment also compete for funds. Look for parent-level liquidity and the expected timing of government and provider payments before treating the cash-flow statement as a distribution policy.

Does Oscar's Thrive distribution create dilution? The announced September event distributed existing shares. It is distinct from company issuance, employee equity compensation or a convertible security becoming shares. Those other mechanisms require their own filings and share-count analysis. Existing holders can change without the company receiving proceeds or increasing its total shares.

Is a guidance raise enough to confirm a recovery? It improves the disclosed outlook but does not establish permanence. Compare the revised range with the current-year claims experience, earlier-period benefits and assumptions for the remaining months. Oscar's September change, CVS's prior-year bridge, Centene's nonrecurring items and UnitedHealth's service-date distinction illustrate why the explanation accompanying guidance deserves as much attention as the new number.

22Your reusable reading sequence and the source trail

Begin with the covered population and the period. Reconcile membership snapshots to the months generating premium. Identify which members are fully insured, which relationships are administrative and which products cover only a narrower benefit. Then read the company's ratio definition and use the corresponding premium base. This sequence prevents a large share of the errors that arise when health insurers are analyzed like ordinary subscription businesses.

Next reconstruct the earnings bridge. Separate current claims experience, pricing, mix, risk-adjustment revisions, claims development and unusual comparison items. Match each adjustment to the service year or policy year when the company provides that information. Reconcile the profit with cash timing and insurance liabilities, then identify the capital remaining at the parent after operating needs. Only after those steps should membership growth, adjusted EPS and a market multiple become a valuation argument.

The core company evidence is the Centene Q2 release and financial tables, CVS Q2 SEC exhibit and presentation, Oscar Q2 filing and September 16 update, plus UnitedHealth Q2 filing. Company releases and their SEC exhibits can corroborate transcription, although they remain the same issuer's account rather than independent audits of management's expectations.

For program mechanics, consult CMS risk-adjustment resources, CMS medical-loss-ratio guidance, the 2027 Medicare payment announcement and Medicaid rate-development materials. The numerical examples are hypothetical rather than company forecasts. More members are worth more when the obligations they bring can be served well, funded adequately and priced to leave a durable residual for each share.